Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
250 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Eli Lilly and Company - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Eli Lilly and Company - Product Pipeline Review - 2014', provides an overview of the Eli Lilly and Company's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Eli Lilly and Company's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Eli Lilly and Company including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Eli Lilly and Company's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Eli Lilly and Company's pipeline products Reasons to buy - Evaluate Eli Lilly and Company's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Eli Lilly and Company in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Eli Lilly and Company's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Eli Lilly and Company and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Eli Lilly and Company - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Eli Lilly and Company and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Eli Lilly and Company Snapshot 7 Eli Lilly and Company Overview 7 Key Information 7 Key Facts 7 Eli Lilly and Company - Research and Development Overview 8 Key Therapeutic Areas 8 Eli Lilly and Company - Pipeline Review 17 Pipeline Products by Stage of Development 17 Pipeline Products - Monotherapy 18 Pipeline Products - Partnered Products 19 Pipeline Products - Out-Licensed Products 22 Eli Lilly and Company - Pipeline Products Glance 25 Eli Lilly and Company - Late Stage Pipeline Products 25 Eli Lilly and Company - Clinical Stage Pipeline Products 29 Eli Lilly and Company - Early Stage Pipeline Products 36 Eli Lilly and Company - Drug Profiles 39 cetuximab 39 dulaglutide 46 insulin glargine 49 ramucirumab 51 tadalafil 56 vancomycin 58 baricitinib 59 duloxetine hydrochloride DR 61 evacetrapib 63 insulin peglispro 65 ixekizumab 67 LY-2835219 68 necitumumab 69 solanezumab 71 tabalumab 73 teriparatide 75 edivoxetine 77 galunisertib 79 blosozumab 81 emibetuzumab 82 erteberel 83 gandotinib 84 icrucumab 86 LY-2090314 87 LY-2409021 88 LY-2495655 89 LY-2510924 90 LY-2606368 91 LY-2801653 92 LY-2928057 93 LY-2940094 94 LY-2944876 95 LY-2951742 96 LY-3015014 97 LY-3016859 98 olaratumab 99 pemetrexed disodium 101 ralimetinib mesylate 107 taladegib 108 LY-3053102 109 Biologic 3 For Diabetes 110 Biologic 4 For Diabetes 111 Biologic for Crohn's Disease 112 Biologic For Lupus 113 Biologic-5 for Diabetes 114 IMC-3C5 115 IMC-CS4 116 LY-2780301 117 LY-2787106 118 LY-2874455 119 LY-2922083 120 LY-2922470 121 LY-2969822 122 LY-2979165 123 LY-3002813 124 LY-3006072 125 LY-3009120 126 LY-3022859 128 LY-3023414 129 LY-3025876 131 LY-3039478 132 LY-3045697 133 LY-3050258 134 LY-3074828 135 LY-3084077 136 LY-3090106 137 LY-3108743 138 LY-3127760 139 LY-404039 140 Small Molecule 1 for Diabetes 142 Small Molecule For Chronic Kidney Disease 143 Small Molecule for Hypertension 144 Small Molecule for Muscle Atrophy 145 Small Molecule to Agonize mGlu2/3 for Chronic Pain 146 Small Molecule to Antagonize EP4 Receptor for Osteoarthritis Pain 147 TT-401 148 cercosporamide 149 CPZEN-45 151 LLY-2707 152 LSN-2463359 153 LSN-2535717 154 LSN-2814617 155 LY-2109761 156 LY-2607540 157 LY-2857785 158 LY-364937 159 LYTAK-1 160 Monoclonal Antibody For Oncology 161 ND-09759 162 Peptide For Type 2 Diabetes And Obesity 163 Small Molecule to Inhibit mGlu5 for Pain 164 Bispecific Monoclonal Antibodies For Oncology 165 Polycyclic Guanidine Derivative for Type 2 Diabetes 166 Small Molecules to Inhibit Beta Secretase for Alzheimer's Disease 167 Eli Lilly and Company - Pipeline Analysis 168 Eli Lilly and Company - Pipeline Products by Target 168 Eli Lilly and Company - Pipeline Products by Route of Administration 173 Eli Lilly and Company - Pipeline Products by Molecule Type 174 Eli Lilly and Company - Pipeline Products by Mechanism of Action 176 Eli Lilly and Company - Recent Pipeline Updates 181 Eli Lilly and Company - Dormant Projects 208 Eli Lilly and Company - Discontinued Pipeline Products 217 Discontinued Pipeline Product Profiles 219 Eli Lilly and Company - Company Statement 229 Eli Lilly and Company - Locations And Subsidiaries 233 Head Office 233 Other Locations & Subsidiaries 233 Eli Lilly and Company - Key Manufacturing Facilities 240 Appendix 241 Methodology 241 Coverage 241 Secondary Research 241 Primary Research 241 Expert Panel Validation 241 Contact Us 242 Disclaimer 242
List of Tables Eli Lilly and Company, Key Information 15 Eli Lilly and Company, Key Facts 15 Eli Lilly and Company - Pipeline by Indication, 2014 17 Eli Lilly and Company - Pipeline by Stage of Development, 2014 25 Eli Lilly and Company - Monotherapy Products in Pipeline, 2014 26 Eli Lilly and Company - Partnered Products in Pipeline, 2014 27 Eli Lilly and Company - Partnered Products/ Combination Treatment Modalities, 2014 28 Eli Lilly and Company - Out-Licensed Products in Pipeline, 2014 30 Eli Lilly and Company - Out-Licensed Products/ Combination Treatment Modalities, 2014 31 Eli Lilly and Company - Pre-Registration, 2014 33 Eli Lilly and Company - Filing rejected/Withdrawn, 2014 34 Eli Lilly and Company - Phase III, 2014 35 Eli Lilly and Company - Phase II, 2014 37 Eli Lilly and Company - Phase I, 2014 40 Eli Lilly and Company - Preclinical, 2014 44 Eli Lilly and Company - Discovery, 2014 46 Eli Lilly and Company - Pipeline by Target, 2014 177 Eli Lilly and Company - Pipeline by Route of Administration, 2014 181 Eli Lilly and Company - Pipeline by Molecule Type, 2014 183 Eli Lilly and Company - Pipeline Products by Mechanism of Action, 2014 184 Eli Lilly and Company - Recent Pipeline Updates, 2014 189 Eli Lilly and Company - Dormant Developmental Projects,2014 216 Eli Lilly and Company - Discontinued Pipeline Products, 2014 225 Eli Lilly and Company, Subsidiaries 241 Eli Lilly and Company, Key Manufacturing Facilities 248
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
